APTO News and Press, Aptose Biosciences Inc. From 03/02/21

SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter end...

Aptose shares are weak in post-ASH trading as the Phase I CG-806 study has yet to produce a clinical response in B-cell malignancies. Three B-cell patients did see some tumor reduction at lower doses of CG-806, and the expansion to 750mg (and possibly higher doses) could finally drive...

Meten EdtechX Education Group (METX) -23% on temporary offer allowing warrants to be exercised at a reduced price of $1.40 per share.Obalon Therapeutics (OBLN) -16%.Francesca's Holdings (FRAN) -13% on notice of delisting from NASDAQ, after it files for bankruptcy.SenesTech (SNES) -1...

Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...

Gainers: Obalon Therapeutics (OBLN) +116%, Oncternal Therapeutics (ONCT) +77%, Fate Therapeutics (FATE) +41%, Constellation Pharmaceuticals (CNST) +33%, Nkarta (NKTX) +28%.Losers: scPharmaceuticals (SCPH) -33%, Aptose Biosciences (APTO) -...

Oppenheimer updates on the investor event held by Aptose Biosciences (APTO) at the ASH conference yesterday. "Several CLL/NHL patients in CG-806's Phase 1 trial have shown tumor size reductions, although no objective responses were observed. Since EHA, dosing has escalated to 750 mg BID, but ...

scPharmaceuticals (SCPH) -40% on complete response letter from FDA for FUROSCIX.Lyra Therapeutics, Inc. (LYRA) -28% on positive topline results for LANTERN phase 2 randomized controlled study of LYR-210 for the treatment of chronic rhinosinusitis with and without nasal polyps.A...

SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December 6 th , in conjunction with participation at the 2020 American Society of He...

Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers Poster Presentations for CG-806 and APTO-253 are scheduled for December 5 th and 6 th at 2020 ASH Annual Meeting and Exposition SAN DIEGO and TORON...

Nonsteroidal anti-inflammatory drugs, or NSAIDs are among the most widely used medications in the world for pain and inflammation. In fact, more than 33 million Americans use them regularly, and more than 30 billion doses of NSAIDs are administered annually in the U.S., according to Medicin...